A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;2021(71):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M; Global Burden of Disease Liver Cancer Collaboration. et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease Study 2015. JAMA Oncol. 3;2017:1683–1691. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394:1145–1158. doi:10.1016/S0140-6736(19)30427-1
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72:250–261. doi:10.1016/j.jhep.2019.08.025
   PubMed Web of Science ®Google Scholar
• Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006;96:223–268.
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763. doi:10.1056/NEJM199512283332608
   PubMed Web of Science ®Google Scholar
• Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–407. doi:10.1038/37126
   PubMed Web of Science ®Google Scholar
• Al-Husein B, Abdalla M, Trepte M, et al. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32:1095–1111. doi:10.1002/phar.1147
   PubMed Web of Science ®Google Scholar
• Kerbel RS. A decade of experience in developing preclinical models of advanced- or early-stage spontaneous metastasis to study antiangiogenic drugs, metronomic chemotherapy, and the tumor microenvironment. Cancer J. 2015;21:274–283. doi:10.1097/PPO.0000000000000134
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2017;389:56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Li Q, Qin S, Gu S, et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: a randomized, placebo-controlled, double-blind, phase III study. J Clin Oncol. 2020;38(15_suppl):4507. doi:10.1200/JCO.2020.38.15_suppl.4507
   Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37(15_suppl):4004. doi:10.1200/JCO.2019.37.15_suppl.4004
   Web of Science ®Google Scholar
• Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, Phase 2 trial. Lancet Oncol. 2020;21:571–580. doi:10.1016/S1470-2045(20)30011-5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fan W, Wang Y, et al. Apatinib for patients with sorafenib-refractory advanced hepatitis B virus related hepatocellular carcinoma: results of a pilot study. Cancer Control. 2019;26:1073274819872216. doi:10.1177/1073274819872216
   Web of Science ®Google Scholar
• Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018;654:77–86. doi:10.1016/j.gene.2018.02.026
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett. 2020;20:1001–1014. doi:10.3892/ol.2020.11685
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109:1207–1219. doi:10.1111/cas.13536
   PubMed Web of Science ®Google Scholar
• Granito A, Forgione A, Marinelli S, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021;14:17562848211016959. doi:10.1177/17562848211016959
   Web of Science ®Google Scholar
• Granito A, Muratori L, Lalanne C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021;27(22):2994–3009. doi:10.3748/wjg.v27.i22.2994
   PubMed Web of Science ®Google Scholar
• Liu S, Qin T, Liu Z, et al. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309. doi:10.1038/s41419-020-2511-3
   PubMed Web of Science ®Google Scholar
• Guo W, Chen S, Wu Z, et al. Efficacy and safety of transarterial chemoembolization combined with anlotinib for unresectable hepatocellular carcinoma: a retrospective study. Technol Cancer Res Treat. 2020;19:1533033820965587. doi:10.1177/1533033820965587
   Web of Science ®Google Scholar
• Han C, Ye S, Hu C, et al. Clinical activity and safety of Penpulimab (anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-label, multicenter, phase Ib/II trial (AK105-203). Front Oncol. 2021;11:684867. doi:10.3389/fonc.2021.684867
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhou A, Zhang W, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label Phase II study (ALTER-0802 study). Hepatol Int. 2021;15:621–629. doi:10.1007/s12072-021-10171-0
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55:113–122. doi:10.1007/s00535-019-01642-1
   PubMed Web of Science ®Google Scholar
• Qin S, Ren Z, Feng YH, et al. Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver Cancer. 2021;10:296–308. doi:10.1159/000513486
   PubMed Web of Science ®Google Scholar
• Wang DX, Yang X, Lin JZ, et al. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: a retrospective, real-world study conducted in China. World J Gastroenterol. 2020;26:4465–4478. doi:10.3748/wjg.v26.i30.4465
   PubMed Web of Science ®Google Scholar
• Sasaki R, Fukushima M, Haraguchi M, et al. Response to lenvatinib is associated with optimal RelativeDose intensity in hepatocellular carcinoma: experience in clinical settings. Cancers. 2018;11:1769.
   Web of Science ®Google Scholar
• Terashima T, Yamashita T, Takata N, et al. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatol Res. 2020;50:871–884. doi:10.1111/hepr.13505
   PubMed Web of Science ®Google Scholar
• Amino N, Ideyama Y, Yamano M, et al. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res. 2006;12:1630–1638. doi:10.1158/1078-0432.CCR-05-2028
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:251–258. doi:10.1159/000334454
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999–1008. doi:10.1016/j.jhep.2017.06.026
   PubMed Web of Science ®Google Scholar
• Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology. 2012;83:192–200. doi:10.1159/000341347
   PubMed Web of Science ®Google Scholar
• Kodama K, Kawaoka T, Namba M, et al. Correlation between early tumor marker response and imaging response in patients with advanced hepatocellular carcinoma treated with lenvatinib. Oncology. 2019;97:75–81. doi:10.1159/000499715
   PubMed Web of Science ®Google Scholar
• Shen LYZ, Guo Y, WL JF, et al. A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC). Ann Oncol. 2020;1(4):987.
   Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus Pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24:5233–5238. doi:10.1158/1078-0432.CCR-17-3766
   PubMed Web of Science ®Google Scholar
• Cheng Y, Han B, Li K, et al. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial. Cancer Med. 2020;9:2621–2630. doi:10.1002/cam4.2913
   PubMed Web of Science ®Google Scholar
• Zhou AP, Bai Y, Song Y, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized Phase II clinical trial. Oncologist. 2019;24:e702–e708. doi:10.1634/theoncologist.2018-0839
   PubMed Web of Science ®Google Scholar
• Feng S, Feng HF, Xu J, et al. Value of Fibro Scan and platelet count-to-spleen thickness ratio in predicting the degree of esophageal and gastric varices in liver cirrhosis. J Clin Hepatol. 2021;37:2819–2823.
   Google Scholar